First, a combination of IFN subtypes (e.g., HerberFERON) can improve the IFN therapy potency against basal cell carcinomas, glioblastomas, and renal cell carcinomas. The gene discussed is IFNA1; the disease is hereditary clear cell renal cell carcinoma.